Companies: 10,795·Total market cap: $144.5T
Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

EWTXNASDAQHealthcare● Active
$35.64
+$0.05(+0.15%)
Market Cap$3.8B
P/E Ratio
52W High$40.765
52W Low$12.15
SEC Filings

Edgewise Therapeutics, Inc. (EWTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001710072 · EWTX · NASDAQ · as of Jun 8, 2026

Filing snapshot

388
Total Filings
8-K
Latest Form
2026-06-05
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001710072 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001104659-26-020112
Primary Document
ewtx-20251231x10k.htm
Source: data.sec.gov · CIK 0001710072 · Accession 0001104659-26-020112

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
FORM 8-K
2026-06-05Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
FORM 8-K
2026-06-05
View
8-KCurrent Report
8-K
2026-06-01
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
S-8Employee Stock Plan Registration
FORM S-8
2026-05-07
View
8-KCurrent Report
FORM 8-K
2026-05-07
View
10-QQuarterly Report
10-Q
2026-05-07
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-04-27
View
ARSARS
ARS
2026-04-23
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-23
View
DEF 14AProxy Statement
DEF 14A
2026-04-23
View
10-KAnnual Report
10-K
2026-02-26
View
8-KCurrent Report
FORM 8-K
2026-02-26
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
3Initial Statement of Beneficial Ownership
PRIMARY DOCUMENT
2025-11-24
View
8-KCurrent Report
FORM 8-K
2025-11-20
View
Showing 1–15 of 204 filingsForm 4 / 144 hidden· 388 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001710072  |  Exchange: NASDAQ · Healthcare

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) has submitted 388 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001710072, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Edgewise Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Edgewise Therapeutics, Inc. 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical EWTX 10-K annual reports are available from 2019 through 2026.

Investors researching Edgewise Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

EWTX SEC Filings · 8 questions

Edgewise Therapeutics, Inc. (EWTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 388 filings and access original documents at no cost. Edgewise Therapeutics, Inc.'s CIK is 0001710072.

EWTX SEC filingsEdgewise Therapeutics, Inc. SEC documentsfind EWTX 10-K